-

$undefined

N/A

(N/A)

Aclaris Therapeutics Inc. NASDAQ:ACRS Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation.

Location: 640 Lee Rd Ste 200, Pennsylvania, 19087-5636, US | Website: www.aclaristx.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

68.82M

Cash

127.7M

Avg Qtr Burn

-4.475M

Short % of Float

4.49%

Insider Ownership

3.65%

Institutional Own.

90.21%

Qtr Updated

09/30/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ATI-1777 (JAK 1/3 inhibitor) Details Atopic dermatitis, Skin disease/disorder	Phase 2b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ATI-2138 (ITK/JAK3 inhibitor) Details Skin disease/disorder, Atopic dermatitis	Phase 2a Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zunsemetinib (ATI-450) (MK2 inhibitor) Details Psoriatic arthritis	Phase 2a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ATI-2138 (ITK/JAK3 inhibitor) Details Autoimmune disease, Ulcerative colitis	Phase 2a Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ATI-2231 (MK2 inhibitor) Details Solid tumor/s, Cancer, Pancreatic cancer, Metastatic breast cancer	Phase 1a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zunsemetinib (ATI-450) (MK2 inhibitor) Details Hidradenitis suppurativa	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zunsemetinib (ATI-450) Details COVID-19	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zunsemetinib (ATI-450) Details Rheumatoid arthritis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.